This test sounds awfully similar to Trinity's. Anybody know the details?
<SPECTRAL DIAGNOSTICS USA MARKETS RAPID FORMAT TROPONIN I
ST. FRANCIS HOSPITAL OF EVANSTON, ILLINOIS, A LEADER IN CARDIAC
CARE, IS FIRST US HOSPITAL TO USE SPECTRAL'S NEW POINT OF CARE
TROPONIN I
Source: PR Newswire
TORONTO, Dec. 4 /CNW-PRN/ via Individual Inc. -- Spectral Diagnostics
Inc. (TSE-SDI; NASDAQ- DIAGF), announced that St. Francis Hospital of
Evanston, Illinois is the first US hospital to begin using Spectral's
Cardiac STATus(TM) rapid format Troponin I panel test. Spectral received
Food and Drug Administration (FDA) 510(K) marketing clearance in November
for the Troponin I panel test, the industry's first point of care rapid
Troponin I assay.
In a separate press release dated December 3, 1996, St. Francis Hospital
made the following announcement:
St. Francis Hospital of Evanston is the first hospital in the country to
begin using the Cardiac STATus Troponin I Rapid Assay test developed by
Spectral Diagnostics & Princeton BioMedica, Inc. This comes just following
the U.S. Food & Drug Administrations (marketing) approval for use.
``This is an exciting new test that will enable us to diagnose patients
both accurately and rapidly,'' says Shahriar Dadkhah, M.D., Director of
Cardiovascular Research at St. Francis. ``This test will help us to confirm
that a patient is having a heart attack and thus enable us to initiate
appropriate treatment rapidly, such as angioplasty or thrombolytics. The
earlier we can definitively treat these patients, the more heart muscle we
can preserve. This means a better future for our patients.
This qualitative, hand-held rapid test detects cardiac Troponin I, a
cardiac-specific protein. This test is extremely sensitive and specific
for myocardial injury. This test can help us to rapidly and accurately
identify heart muscle injury such as in a heart attack. It is also sensitive
enough to show minor damage that may be occurring as with unstable angina or
other such cardiac conditions.''
Dr. Dadkhah adds, ``we are trying to diagnose not only when a heart attack
is occurring, but also to diagnose those patients that are having minor
myocardial injury now that are strongly indicative of an impending cardiac
event. This is the focus of cardiology for the year 2000.''
The rapid test is designed for use at the patient's bedside complementing
other existing cardiac markers. It is easy to use with just a few drops of
whole blood required. The results can be read in 15 minutes or less. Its
case of use and speed of results make this test ideal for use in the
Emergency Department, the critical care units, free-standing care units and
other areas in and out of the hospital where a rapid decision regarding a
patient's status is important.
St. Francis Hospital has been a leader in cardiac care for many years with
their advances in both cardiac surgery and invasive cardiology. This new test
is yet another way that St. Francis Hospital's Chest Pain Centre is developing
the most advanced methods of caring for their patients.
Commenting on the St. Francis Hospital press release, Douglas C. Ball,
Chairman and CEO of Spectral Diagnostics Inc. said, ``We're delighted to
have St. Francis Hospital as the inaugural site using our Troponin I panel test.
We believe that our Troponin I panel test is in keeping with the reputation of
St. Francis Hospital for providing the most advanced methods of caring for
their patients.''
According to Mr. Ball, ``Several other hospital and pre-hospital settings Lire
expected to soon follow St. Francis Hospital's commercial example in the use
of Troponin I in order to advance the diagnosis and care of chest pain
patients.''
Located in Canada, the United States and Europe, Spectral's scientists, sales
and marketing organizations and other professionals are focused on the
development, manufacturing and commercialization of its Cardiac
STATus(TM) line of diagnostic panel tests including the CK-MB/Myoglobin
Panel Test, the Troponin I Panel Test and the patented Cardiac Panel(TM).
Spectral's common shares are listed on The Toronto Stock Exchange (symbol
(SDI) and the NASDAQ - NMS - Exchange (symbol DIAGF).
The matters set forth in this press release are forward-looking statements
within the meaning of the ``safe harbor'' provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ materially.
These risks are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission including the Company's
Annual Report, Quarterly Reports and other periodic filings. These
forward-looking statements speak only as of the date hereof. The Company
disclaims any intent or obligation to update these forward-looking statements.
Spectral's common shares are listed on the NASDAQ Exchange (Symbol -
DIAGF) in the United States and the Toronto Stock Exchange ``TSE'' in
Canada (Symbol - SDI)
SOURCE Spectral Diagnostics Inc.
/CONTACT: At Spectral Diagnostics Inc.: Douglas C. Ball, Chairman and
CEO, (416) 626-3233; At Spectral Diagnostics USA: Donna J. Edmonds,
Vice President US Operations, (804) 435-9850/ (SDI. DIAGF)
[12-04-96 at 16:44 EST, PR Newswire]> |
